✦ LIBER ✦

An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for Human Epidermal Growth Factor Receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer

✍ Scribed by Bonnefoi, H.; Zaman, K.; Debled, M.; Fiche, M.; Fournier, M.; Nobahar, M.; Pierga, J-Y; Koch, K.M.; Bartlett, J.; Zimmer, A.; Marreaud, S.; Bogaerts, J.; Cameron, D.

Book ID: 123575854
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 397 KB
Volume: 49
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2012.08.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

8N Similar outcome in a randomized phase

✍ M. Andersson; E. Lidbrink; E. Wist; K. Enevoldsen; A.B. Jensen; P.G. Sørensen; K 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 43 KB

An EORTC phase I study of capecitabine (

An EORTC phase I study of capecitabine (Xeloda®) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer

✍ H. Bonnefoi; L. Biganzoli; L. Mauriac; T. Cufer; P. Schaefer; G. Atalay; M. Picc 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 214 KB